INVESTIGACIÓN

 
  • Grupos de Investigación
  • Unidades de Investigación
  • Memoria Cientifíca
  • Publicaciones
espacio

 

PUBLICACIONES

 

 

spacerTrabajos Publicados por Isabel Lastres Becker
spacer
  1. Burgaz, S.; Navarro, E.; Rodríguez-Carreiro, S.; Navarrete, C.; Garrido-Rodríguez, M.; Lastres-Becker, I.; Chocarro, J.; Lanciego, J.L.; Muñoz, E.; Fernández-Ruiz, J. "Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy.". Behav Brain Funct. 20(1): 28. (2024). (PMID: 39487447).
    spacer

  2. Silva-Llanes, I.; Martín-Baquero, R.; Berrojo-Armisen, A.; Rodríguez-Cueto, C.; Fernández-Ruiz, J.; De Lago, E.; Lastres-Becker, I. "Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia.". Antioxidants (Basel). 13(9): . (2024). (PMID: 39334731).
    spacer

  3. Morgenstern, C.; Lastres-Becker, I.; Demirdöğen, B.C.; Costa, V.M.; Daiber, A.; Foresti, R.; Motterlini, R.; Kalyoncu, S.; Arioz, B.I.; Genc, S.; Jakubowska, M.; Trougakos, I.P.; Piechota-Polanczyk, A.; Mickael, M.; Santos, M.; Kensler, T.W.; Cuadrado, A.; Copple, I.M. "Biomarkers of NRF2 signalling: Current status and future challenges.". Redox Biol. 72(): 103134. (2024). (PMID: 38643749).
    spacer

  4. Brackhan, M.; Arribas-Blazquez, M.; Lastres-Becker, I. "Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration?". Antioxidants (Basel). 12(8): . (2023). (PMID: 37627559).
    spacer

  5. Lastres-Becker, I. "Special Issue "Role of NRF2 in Disease: Novel Molecular Mechanisms and Therapeutic Approaches II".". Biomolecules. 13(5): . (2023). (PMID: 37238683).
    spacer

  6. Silva-Llanes, I.; Shin, C.H.; Jiménez-Villegas, J.; Gorospe, M.; Lastres-Becker, I. "The Transcription Factor NRF2 Has Epigenetic Regulatory Functions Modulating HDACs, DNMTs, and miRNA Biogenesis.". Antioxidants (Basel). 12(3): . (2023). (PMID: 36978889).
    spacer

  7. Lastres-Becker, I.; de Lago, E.; Martínez, A.; Fernández-Ruiz, J. "New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.". Biomolecules. 12(9): . (2022). (PMID: 36139039).
    spacer

  8. Martín-Cámara, O.; Arribas, M.; Wells, G.; Morales-Tenorio, M.; Martín-Requero, Á.; Porras, G.; Martínez, A.; Giorgi, G.; López-Alvarado, P.; Lastres-Becker, I.; Menéndez, J.C. "Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis.". J Med Chem. (): . (2022). (PMID: 34985276).
    spacer

  9. Lastres-Becker, I. "Editorial: Tau Protein: Mechanisms From Health to Degeneration.". Front Mol Neurosci. 14(): 743986. (2021). (PMID: 34790096).
    spacer

  10. García-Yagüe, Á.J.; Lastres-Becker, I.; Stefanis, L.; Vassilatis, D.K.; Cuadrado, A. "α-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks.". Mol Neurobiol. (): . (2021). (PMID: 34609698).
    spacer

  11. Galán-Ganga, M.; Rodríguez-Cueto, C.; Merchán-Rubira, J.; Hernández, F.; Ávila, J.; Posada-Ayala, M.; Lanciego, J.L.; Luengo, E.; Lopez, M.G.; Rábano, A.; Fernández-Ruiz, J.; Lastres-Becker, I. "Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration.". Acta Neuropathol Commun. 9(1): 90. (2021). (PMID: 34001284).
    spacer

  12. Lastres-Becker, I.; Porras, G.; Arribas-Blázquez, M.; Maestro, I.; Borrego-Hernández, D.; Boya, P.; Cerdán, S.; García-Redondo, A.; Martínez, A.; Martin-Requero, Á. "Molecular Alterations in Sporadic and SOD1-ALS Immortalized Lymphocytes: Towards a Personalized Therapy.". Int J Mol Sci. 22(6): . (2021). (PMID: 33809456).
    spacer

  13. Klionsky, D.J.; [ .., ].; Bartolome, A.; [ .., ].; Cuadrado, A.; [ .., ].; Escalante, R.; [ .., ].; García-Sanz, P.; [ .., ].; Lastres-Becker, I.; [ .., ].; León, Y.; [ .., ].; Martin-Sanz, P.; [ .., ].; Pajares, M.; [ .., ].; Rojo, A.I.; [ .., ].; Valverde, A.M.; [ .., ].; Varela-Nieto, I.; [ .., ].; Villalobo, A.; [ .., ].; Vincent, O.; [ .., ].; Tong, C.K. "Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).". Autophagy. (): 1-382. (2021). (PMID: 33634751).
    spacer

  14. Lastres-Becker, I. "Special Issue "Role of NRF2 in Disease: Novel Molecular Mechanisms and Therapeutic Approaches".". Biomolecules. 11(2): . (2021). (PMID: 33540503).
    spacer

  15. Castro-Sánchez, S.; Zaldivar-Diez, J.; Luengo, E.; López, M.G.; Gil, C.; Martínez, A.; Lastres-Becker, I. "Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model.". Neurobiol Aging. 96(): 148-154. (2020). (PMID: 33007689).
    spacer

  16. Martin-Hurtado, A.; Lastres-Becker, I.; Cuadrado, A.; Garcia-Gonzalo, F.R. "NRF2 and Primary Cilia: An Emerging Partnership.". Antioxidants (Basel). 9(6): . (2020). (PMID: 32498260).
    spacer

  17. Martin-Hurtado, A.; Martin-Morales, R.; Robledinos-Antón, N.; Blanco, R.; Palacios-Blanco, I.; Lastres-Becker, I.; Cuadrado, A.; Garcia-Gonzalo, F.R. "NRF2-dependent gene expression promotes ciliogenesis and Hedgehog signaling.". Sci Rep. 9(1): 13896. (2019). (PMID: 31554934).
    spacer

  18. Galán-Ganga, M.; Del Río, R.; Jiménez-Moreno, N.; Díaz-Guerra, M.; Lastres-Becker, I. "Cannabinoid CB2 Receptor Modulation by the Transcription Factor NRF2 is Specific in Microglial Cells.". Cell. Mol. Neurobiol.. (): . (2019). (PMID: 31385133).
    spacer

  19. Galán-Ganga, M.; García-Yagüe, Á.J.; Lastres-Becker, I. "Role of MSK1 in the Induction of NF-κB by the Chemokine CX3CL1 in Microglial Cells.". Cell. Mol. Neurobiol.. 39(3): 331-340. (2019). (PMID: 30830503).
    spacer

  20. Castro-Sánchez, S.; García-Yagüe, Á.J.; Kügler, S.; Lastres-Becker, I. "CX3CR1-deficient microglia shows impaired signalling of the transcription factor NRF2: Implications in tauopathies.". Redox Biol. 22(): 101118. (2019). (PMID: 30769286).
    spacer

  21. Castro-Sánchez, S.; García-Yagüe, Á.J.; López-Royo, T.; Casarejos, M.; Lanciego, J.L.; Lastres-Becker, I. "Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.". Glia. 66(8): 1752-1762. (2018). (PMID: 29624735).
    spacer

  22. Cuadrado, A.; Kügler, S.; Lastres-Becker, I. "Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.". Redox Biol. 14(): 522-534. (2017). (PMID: 29121589).
    spacer

  23. Lastres-Becker, I.; Nonis, D.; Eich, F.; Klinkenberg, M.; Gorospe, M.; Kötter, P.; Klein, F.A.; Kedersha, N.; Auburger, G. "Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K/mTOR and is induced by starvation.". Biochim. Biophys. Acta. 1862(9): 1558-1569. (2016). (PMID: 27240544).
    spacer

  24. Lastres-Becker, I.; García-Yagüe, A.J.; Scannevin, R.H.; Casarejos, M.J.; Kügler, S.; Rábano, A.; Cuadrado, A. "Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease.". Antioxid. Redox Signal.. 25(2): 61-77. (2016). (PMID: 27009601).
    spacer

  25. Fittschen, M.; Lastres-Becker, I.; Halbach, M.V.; Damrath, E.; Gispert, S.; Azizov, M.; Walter, M.; Müller, S.; Auburger, G. "Genetic ablation of ataxin-2 increases several global translation factors in their transcript abundance but decreases translation rate.". Neurogenetics. 16(3): 181-192. (2015). (PMID: 25721894).
    spacer

  26. Delgado-Buenrostro, N.L.; Medina-Reyes, E.I.; Lastres-Becker, I.; Freyre-Fonseca, V.; Ji, Z.; Hernández-Pando, R.; Marquina, B.; Pedraza-Chaverri, J.; Espada, S.; Cuadrado, A.; Chirino, Y.I. "Nrf2 protects the lung against inflammation induced by titanium dioxide nanoparticles: A positive regulator role of Nrf2 on cytokine release.". Environ. Toxicol.. 30(7): 782-792. (2015). (PMID: 24615891).
    spacer

  27. Cuadrado, A.; Martín-Moldes, Z.; Ye, J.; Lastres-Becker, I. "Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation.". J. Biol. Chem.. 289(22): 15244-15258. (2014). (PMID: 24759106).
    spacer

  28. Lastres-Becker, I.; Innamorato, N.G.; Jaworski, T.; Rábano, A.; Kügler, S.; Van Leuven, F.; Cuadrado, A. "Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis.". Brain. 137(Pt 1): 78-91. (2014). (PMID: 24277722).
    spacer

  29. Martín-de-Saavedra, M.D.; Budni, J.; Cunha, M.P.; Gómez-Rangel, V.; Lorrio, S.; Del Barrio, L.; Lastres-Becker, I.; Parada, E.; Tordera, R.M.; Rodrigues, A.L.; Cuadrado, A.; López, M.G. "Nrf2 participates in depressive disorders through an anti-inflammatory mechanism.". Psychoneuroendocrinology. 38(10): 2010-2022. (2013). (PMID: 23623252).
    spacer

  30. Drost, J.; Nonis, D.; Eich, F.; Leske, O.; Damrath, E.; Brunt, E.R.; Lastres-Becker, I.; Heumann, R.; Nowock, J.; Auburger, G. "Ataxin-2 modulates the levels of Grb2 and SRC but not ras signaling.". J. Mol. Neurosci.. 51(1): 68-81. (2013). (PMID: 23335000).
    spacer

  31. García-Yagüe, Á.J.; Rada, P.; Rojo, A.I.; Lastres-Becker, I.; Cuadrado, A. "Nuclear import and export signals control the subcellular localization of Nurr1 protein in response to oxidative stress.". J. Biol. Chem.. 288(8): 5506-5517. (2013). (PMID: 23283970).
    spacer

  32. Lastres-Becker, I.; Ulusoy, A.; Innamorato, N.G.; Sahin, G.; Rábano, A.; Kirik, D.; Cuadrado, A. "α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.". Hum. Mol. Genet.. 21(14): 3173-3192. (2012). (PMID: 22513881).
    spacer

  33. Granado, N.; Lastres-Becker, I.; Ares-Santos, S.; Oliva, I.; Martin, E.; Cuadrado, A.; Moratalla, R. "Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum.". Glia. 59(12): 1850-1863. (2011). (PMID: 21882243).
    spacer

  34. Kurz, A.; Double, K.L.; Lastres-Becker, I.; Tozzi, A.; Tantucci, M.; Bockhart, V.; Bonin, M.; García-Arencibia, M.; Nuber, S.; Schlaudraff, F.; Liss, B.; Fernández-Ruiz, J.; Gerlach, M.; Wüllner, U.; Lüddens, H.; Calabresi, P.; Auburger, G.; Gispert, S. "A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.". PLoS ONE. 5(7): e11464. (2010). (PMID: 20628651).
    spacer

  35. Niso-Santano, M.; González-Polo, R.A.; Bravo-San Pedro, J.M.; Gómez-Sánchez, R.; Lastres-Becker, I.; Ortiz-Ortiz, M.A.; Soler, G.; Morán, J.M.; Cuadrado, A.; Fuentes, J.M.; , . "Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2/Trx axis.". Free Radic. Biol. Med.. 48(10): 1370-1381. (2010). (PMID: 20202476).
    spacer

  36. Sagredo, O.; González, S.; Aroyo, I.; Pazos, M.R.; Benito, C.; Lastres-Becker, I.; Romero, J.P.; Tolón, R.M.; Mechoulam, R.; Brouillet, E.; Romero, J.; Fernández-Ruiz, J. "Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.". Glia. 57(11): 1154-1167. (2009). (PMID: 19115380).
    spacer

  37. Innamorato, N.G.; Lastres-Becker, I.; Cuadrado, A. "Role of microglial redox balance in modulation of neuroinflammation.". Curr. Opin. Neurol.. 22(3): 308-314. (2009). (PMID: 19359988).
    spacer

  38. Lastres-Becker, I.; Fernández-Pérez, A.; Cebolla, B.; Vallejo, M. "Pituitary adenylate cyclase-activating polypeptide stimulates glial fibrillary acidic protein gene expression in cortical precursor cells by activating Ras and Rap1.". Mol. Cell. Neurosci.. 39(3): 291-301. (2008). (PMID: 18707003).
    spacer

  39. Lastres-Becker, I.; Rüb, U.; Auburger, G. "Spinocerebellar ataxia 2 (SCA2).". Cerebellum. 7(2): 115-124. (2008). (PMID: 18418684).
    spacer

  40. Lastres-Becker, I.; Brodesser, S.; Lütjohann, D.; Azizov, M.; Buchmann, J.; Hintermann, E.; Sandhoff, K.; Schürmann, A.; Nowock, J.; Auburger, G. "Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice.". Hum. Mol. Genet.. 17(10): 1465-1481. (2008). (PMID: 18250099).
    spacer

  41. Lastres-Becker, I.; Fernández-Ruiz, J. "An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments.". Curr. Med. Chem.. 13(30): 3705-3718. (2006). (PMID: 17168732).
    spacer

  42. Lastres-Becker, I.; Cartmell, T.; Molina-Holgado, F. "Endotoxin preconditioning protects neurones from in vitro ischemia: role of endogenous IL-1beta and TNF-alpha.". J. Neuroimmunol.. 173(1-2): 108-116. (2006). (PMID: 16439029).
    spacer

  43. Lastres-Becker, I.; Molina-Holgado, F.; Ramos, J.A.; Mechoulam, R.; Fernández-Ruiz, J. "Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.". Neurobiol. Dis.. 19(1-2): 96-9107. (2005). (PMID: 15837565).
    spacer

  44. González, S.; Mena, M.A.; Lastres-Becker, I.; Serrano, A.; de Yébenes, J.G.; Ramos, J.A.; Fernández-Ruiz, J. "Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice.". Brain Res.. 1046(1-2): 195-206. (2005). (PMID: 15882845).
    spacer

  45. Lastres-Becker, I.; Bizat, N.; Boyer, F.; Hantraye, P.; Fernández-Ruiz, J.; Brouillet, E. "Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo.". Neuroreport. 15(15): 2375-2379. (2004). (PMID: 15640759).
    spacer

  46. de Lago, E.; de Miguel, R.; Lastres-Becker, I.; Ramos, J.A.; Fernández-Ruiz, J. "Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence.". Brain Res.. 1007(1-2): 152-159. (2004). (PMID: 15064146).
    spacer

  47. Lastres-Becker, I.; De Miguel, R.; Fernández-Ruiz, J.J. "The endocannabinoid system and Huntington's disease.". Curr Drug Targets CNS Neurol Disord. 2(5): 335-347. (2003). (PMID: 14529364).
    spacer

  48. Lastres-Becker, I.; Bizat, N.; Boyer, F.; Hantraye, P.; Brouillet, E.; Fernández-Ruiz, J. "Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.". Neuroreport. 14(6): 813-816. (2003). (PMID: 12858038).
    spacer

  49. Lastres-Becker, I.; Gómez, M.; De Miguel, R.; Ramos, J.A.; Fernández-Ruiz, J. "Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease.". Neurotox Res. 4(7-8): 601-608. (2003). (PMID: 12709298).
    spacer

  50. Lastres-Becker, I.; de Miguel, R.; De Petrocellis, L.; Makriyannis, A.; Di Marzo, V.; Fernández-Ruiz, J. "Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.". J. Neurochem.. 84(5): 1097-1109. (2003). (PMID: 12603833).
    spacer

  51. Fernández-Ruiz, J.; Lastres-Becker, I.; Cabranes, A.; González, S.; Ramos, J.A. "Endocannabinoids and basal ganglia functionality.". Prostaglandins Leukot. Essent. Fatty Acids. 66(2-3): 257-267. (2002). (PMID: 12052041).
    spacer

  52. Romero, J.; Lastres-Becker, I.; de Miguel, R.; Berrendero, F.; Ramos, J.A.; Fernández-Ruiz, J. "The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.". Pharmacol. Ther.. 95(2): 137-152. (2002). (PMID: 12182961).
    spacer

  53. Lastres-Becker, I.; Hansen, H.H.; Berrendero, F.; De Miguel, R.; Pérez-Rosado, A.; Manzanares, J.; Ramos, J.A.; Fernández-Ruiz, J. "Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.". Synapse. 44(1): 23-35. (2002). (PMID: 11842443).
    spacer

  54. Lastres-Becker, I.; Berrendero, F.; Lucas, J.J.; Martín-Aparicio, E.; Yamamoto, A.; Ramos, J.A.; Fernández-Ruiz, J.J. "Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.". Brain Res.. 929(2): 236-242. (2002). (PMID: 11864629).
    spacer

  55. López-Rodríguez, M.L.; Viso, A.; Ortega-Gutiérrez, S.; Lastres-Becker, I.; González, S.; Fernández-Ruiz, J.; Ramos, J.A. "Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.". J. Med. Chem.. 44(26): 4505-4508. (2001). (PMID: 11741470).
    spacer

  56. Lastres-Becker, I.; Cebeira, M.; de Ceballos, M.L.; Zeng, B.Y.; Jenner, P.; Ramos, J.A.; Fernández-Ruiz, J.J. "Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.". Eur. J. Neurosci.. 14(11): 1827-1832. (2001). (PMID: 11860478).
    spacer

  57. Hansen, H.H.; Schmid, P.C.; Bittigau, P.; Lastres-Becker, I.; Berrendero, F.; Manzanares, J.; Ikonomidou, C.; Schmid, H.H.; Fernández-Ruiz, J.J.; Hansen, H.S. "Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration.". J. Neurochem.. 78(6): 1415-1427. (2001). (PMID: 11579150).
    spacer

  58. Lastres-Becker, I.; Fezza, F.; Cebeira, M.; Bisogno, T.; Ramos, J.A.; Milone, A.; Fernández-Ruiz, J.; Di Marzo, V. "Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.". Neuroreport. 12(10): 2125-2129. (2001). (PMID: 11447320).
    spacer

  59. Di Marzo, V.; Lastres-Becker, I.; Bisogno, T.; De Petrocellis, L.; Milone, A.; Davis, J.B.; Fernandez-Ruiz, J.J. "Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues.". Eur. J. Pharmacol.. 420(2-3): 123-131. (2001). (PMID: 11408034).
    spacer

  60. González, S.; Romero, J.; de Miguel, R.; Lastres-Becker, I.; Villanua, M.A.; Makriyannis, A.; Ramos, J.A.; Fernández-Ruiz, J.J. "Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide.". Life Sci.. 65(3): 327-336. (1999). (PMID: 10447218).
    spacer

  61. Linnertz, H.; Lastres Becker, I.; Krumscheid, R.; Amler, E.; Thoenges, D.; Schoner, W. "2'(3')-O-[N- [2- [3- [5-fluoresceinyl] thioureido] ethyl] carbamoyl] adenosine 5'-triphosphate and its Cr(H2O)4 and Co(NH3)4 complex derivatives are new fluorescent tools for labelling ATP binding sites of Na+/K+-ATPase.". Physiol Res. 46(5): 345-349. (1997). (PMID: 9728479).
    spacer

 

 

 

 

 

Instituto de Investigaciones Biomédicas "Alberto Sols"
C/Arturo Duperier 4. 28029 Madrid. (Spain)
Tel +(34) 91 585 4400 // Fax +(34) 91 558 4401
Email:Info